Vincerx has seen its stock lose 75% of its value after presenting early data from VIP236, its potential first-in-class small-molecule-drug conjugate cancer therapy.
That investor reaction was fueled by Phase I dose-escalation study results that showed that out of 15 patients with metastatic solid tumors treated, only seven patients achieved stable disease and some tumor reduction, and all fell
Key Takeaways
-
Vincerx’s lead asset VIP236 is a small molecule drug conjugate, which aims to overcome drawbacks of antibody-based therapes
-
A further
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?